-
Information-Publications
-
Enhancer RNA transcriptome-wide association study reveals an atlas of pan-cancer susceptibility eRNAsDetails
-
Mechanisms underlying morphological and functional changes of cilia in fibroblasts derived from patients bearing ARL3T31A and ARL3T31A/C118F mutationsDetails
-
Neutralization of SARS-CoV-2 BA. 2.86 and JN. 1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBDDetails
-
Dehydroevodiamine ameliorates neurological dysfunction after traumatic brain injury in mice via regulating the SIRT1/FOXO3a/Bim pathwayDetails
-
Resveratrol attenuates inflammation and fibrosis in rheumatoid arthritis-associated interstitial lung disease via the AKT/TMEM175 pathwayDetails
-
A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB. 1.16, BQ. 1.1 and sarbecovirusesDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands